Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03196973
Other study ID # DF289OT3-16IA01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 22, 2017
Est. completion date September 14, 2018

Study information

Verified date November 2020
Source Salvat
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if a combination of an antibiotic plus a corticosteroid is safe and effective in treating AOE


Recruitment information / eligibility

Status Completed
Enrollment 493
Est. completion date September 14, 2018
Est. primary completion date August 31, 2018
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: - Uncomplicated AOE of less tan 21 days, defined as a total symptom score of at least 2 for otalgia, 2 for edema and 1 for otorrhea - Brighton Grading of II or III - Culture-based diagnosis of acute bacterial otitis externa - Willingness to refrain from swimming through end of the study Exclusion Criteria: - Previous episode of AOE within 4 weeks prior to enrollment, or 2 or more episodes of AOE within 6 months prior to the enrollment. - Tympanic membrane perforation - Any condition or situation likely to cause the patient to be unable or unwilling to comply with study treatment or attend all study visits - Any condition in the patient or parent/guardian that, in the judgment of the principal investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DF289 plus DF277
1 vial into the affected ear twice daily for 7 days
DF289
1 vial into the affected ear twice daily for 7 days
DF277
1 vial into the affected ear twice daily for 7 days

Locations

Country Name City State
Spain Laboratorios SALVAT Esplugues de Llobregat

Sponsors (1)

Lead Sponsor Collaborator
Salvat

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Therapeutic Cure (Clinical + Microbiological Cure) Therapeutic cure will be considered achieved if edema, otalgia and otorrhea are resolved with no further requirement of antimicrobial therapy and bacteriological response is Eradication or Presumed Eradication End of Treatment (Day 8+2)
Secondary Time to End of Pain First day on which there is no use of analgesics, the pain score is zero and remains zero until end of study From baseline to End of Study (Day 15+2)
See also
  Status Clinical Trial Phase
Completed NCT02918773 - Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto) N/A
Not yet recruiting NCT04636957 - A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE) Phase 3
Completed NCT01447017 - A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis Phase 2
Completed NCT01535599 - Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa Phase 3
Completed NCT02801370 - Phase 3 Study of OTO-201 in Acute Otitis Externa Phase 3
Completed NCT00750633 - A Phase III Study of an Otic Formulation in Acute Otitis Externa Phase 3
Terminated NCT00945802 - FST-201 In The Treatment of Acute Otitis Externa Phase 3
Recruiting NCT01584271 - Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R) Phase 2
Completed NCT02216071 - Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa Phase 3
Completed NCT00961675 - FST-201 in the Treatment of Acute Otitis Externa Phase 3
Completed NCT01535560 - Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa Phase 3